Olema Oncology Announces Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", NASDAQ: OLMA), a pioneering clinical-stage biopharmaceutical company specializing in breast cancer therapies, is gearing up for several significant investor conferences. This is a noteworthy period as the company shares insights and strategies with stakeholders.
Highlights of the Investor Conferences
As part of its engagement strategy, Olema will appear at the following prominent conferences:
Guggenheim 2nd Annual Healthcare Innovation Conference
The conference is set for November 10 at 10:30 a.m. ET. Olema's participation will occur in a fireside chat format, providing a platform for discussion and insight exchange.
UBS Global Healthcare Conference 2025
On November 12 at 8:00 a.m. ET, Olema will participate in a presentation format at this crucial healthcare conference, emphasizing their commitment to innovation.
Jefferies London Healthcare Conference 2025
This influential conference will take place on November 19 at 9:00 a.m. GMT / 4:00 a.m. ET, where Olema will again engage in a fireside chat to share their advancements and plans.
Webcasts and Presentation Recaps
Live webcasts of these conferences will be available for viewing on Olema's investor relations website. Potential investors and interested stakeholders can visit the site to access live coverage and recorded sessions from these events.
Core Mission and Vision of Olema Oncology
Olema Oncology is on a mission to redefine standards of care for patients with advanced breast cancer. Their innovative approach is reflected in their drug development, focusing on the discovery and commercialization of targeted therapies. The lead candidate, palazestrant (OP-1250), showcases Olema's dedication to advancing breast cancer treatment. This drug is a complete estrogen receptor antagonist and is currently involved in two pivotal Phase 3 trials.
Insights into Product Pipeline
The company's research doesn't stop with palazestrant. Olema is also exploring OP-3136, a potent KAT6 inhibitor currently in Phase 1 clinical studies. This innovative product pipeline underlines Olema's commitment to tackling breast cancer through diverse therapeutic options.
Company Background
Based in San Francisco, Olema is not just about developing drugs; it’s about making a significant impact on the lives of patients. Their deep understanding of cancer biology, particularly in the context of endocrine-driven cancers, equips them to confront challenges in treatment head-on.
Contact Information for Media Inquiries
For further inquiries, Courtney O'Konek, Vice President of Corporate Communications, is available at media@olema.com. She serves as the primary contact for any media or investor-related questions.
Frequently Asked Questions
What conferences will Olema Oncology participate in?
Olema Oncology will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference, the UBS Global Healthcare Conference, and the Jefferies London Healthcare Conference.
When are the upcoming investor conferences?
The conferences are set for November 10, November 12, and November 19, 2025, at various times.
What is Olema Oncology’s primary focus?
Olema Oncology mainly focuses on discovering and developing targeted therapies for breast cancer and aims to transform patient outcomes.
Where can I find webcasts of the conferences?
Webcasts will be available in the Events and Presentations section of Olema's investor relations website.
Who should I contact for media inquiries?
You can reach Courtney O'Konek at media@olema.com for any media inquiries regarding Olema Oncology.